bluebird bio(BLUE)
Search documents
bluebird bio(BLUE) - 2024 Q1 - Quarterly Report
2024-09-13 20:37
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...
bluebird bio(BLUE) - 2023 Q4 - Annual Report
2024-09-13 20:28
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ FORM 10-K ___________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...
bluebird bio(BLUE) - 2024 Q2 - Earnings Call Transcript
2024-08-14 15:14
bluebird bio, Inc. (NASDAQ:BLUE) Q2 2024 Results Conference Call August 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director of Investor Relations Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer James Sterling - CFO Conference Call Participants Jack Allen - Baird Eric Joseph - JPMorgan Gena Wang - Barclays Jeff Hung - Morgan Stanley Luca Issi - RBC Capital Markets Sami Corwin - William Blair Operator Thank you for standing by. My name is Ken and I will be your confe ...
bluebird bio(BLUE) - 2024 Q2 - Quarterly Results
2024-08-14 11:03
Exhibit 4.1 In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Warrantholder Hercules Capital, Inc. Hercules Private Credit Fund 1 L.P. Hercules Private Global Venture Growth Fund I L.P. THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE ...
CLEAR BLUE STAKEHOLDERS Provide Financing Package of $2.2 - $2.9 Million
GlobeNewswire News Room· 2024-08-06 21:43
TORONTO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Clear Blue Technologies International Inc. (TSXV: CBLU) (the "Company") is pleased to announce that it has received significant financial support from its stakeholders to provide financial support to the Company as it continues to invest in its AI leadership in Smart Power for Internet of Things, Smart City and Telecom markets around the world. The financing consists of the following transactions: SOFII (Southern Ontario Fund for Investment in Innovation), a previo ...
BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2024-06-28 01:00
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bluebird bio Inc. (NASDAQ: BLUE) on behalf of long-term stockholders following a class action complaint that was filed against Blue on March 28, 2024 with a Class Period from April 24, 2023 to December 8, 2023. Our investigation concerns whether the board of directors of Blue have breached their fiduciary duties to the company. Blue is a biot ...
Blue Thunder Mining Inc. Appoints Alain Levesque CFO; Announces Board Change
Newsfile· 2024-06-25 11:00
Montreal, Quebec--(Newsfile Corp. - June 25, 2024) - Blue Thunder Mining Inc. (TSXV: BLUE) ("Blue Thunder" or the "Company") announces that Alain Lévesque will be joining the Company's management team as CFO effective June 25, 2024, replacing Robert Boisjoli who will be resigning his position as CFO effective the same date in order to devote his full attention to other business interests. Mr. Lévesque has 20 years of experience in the field of financial reporting and the management of corporations includin ...
Independent Proxy Advisor Glass Lewis Recommends Medallion Shareholders Vote “FOR” Both of the Board's Director Nominees on the BLUE Proxy Card
GlobeNewswire News Room· 2024-06-04 13:15
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Medallion Financial Corp. (NASDAQ: MFIN) (“Medallion” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recommended that Medallion shareholders vote on the BLUE proxy card “FOR” ONLY the candidates nominated by the Board of Directors, Robert M. Meyer and David L. Rudnick and “FOR” the advisory vote on the compensation of the Company’s named executive officers in connection with the Company’s 2024 Ann ...
Blue Thunder Mining Inc. Changing Name to Orbec Gold Mines Inc., Moving Headquarters to Brossard, Quebec
Newsfile· 2024-06-04 11:00
Montreal, Quebec--(Newsfile Corp. - June 4, 2024) - Blue Thunder Mining Inc. (TSXV: BLUE) ("Blue Thunder" or the "Company") announces that as of its Annual General Meeting to be held on June 6, 2024, and subject to approval at that meeting, the Company will change its name to Orbec Gold Mines Inc. ("Orbec"). The ticker will remain "BLUE" for simplicity and ease of trading as well as for legacy reasons. In addition, the Company is relocating its headquarters to 2000 rue de l'Éclipse, Suite 500, Brossard, Qu ...
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
Prnewswire· 2024-06-03 02:15
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerPost thisDr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in the biopharmaceutical industry leading clinical development of multiple medicines across various therapeutic areas. At Chinook Therapeutics, she advanced the pipeline as Senior VP of Product Development and Strategy, leading to a $3.2 billion acquisition by Novartis. Previously, she was VP of Global Clinical Deve ...